In this episode, you’ll learn what being a cancer survivor means, why the concept of survivorship is important to patients living with myeloma, how to be an empowered advocate for your care, and what to expect day-to-day in your myeloma journey.

MMRF patient navigators Erin Mensching, Grace Allison, and Brittany Hartmann join the podcast to provide up-to-date information on myeloma management, talk about resources that are available to myeloma patients, and offer suggestions on connecting with other myeloma patients, caregivers, and experts.

(0:00) Definition of survivorship

(2:04) Learning the diagnosis

(10:24) Shared decision-making

(39:28) Empowerment through knowledge

This episode is supported by AbbVie, Adaptive, BMS, CURE, Genentech, Kite/Arcellx, Pfizer, Regeneron, and Sanofi.

To learn more about newly diagnosed multiple myeloma, download the Survivorship Fast Facts in Myeloma here.

To learn more about multiple myeloma, visit www.themmrf.org.

If you want to learn more about the MMRF’s FREE resources for patients and caregivers, visit the MMRF Education Hub.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.

In this episode of Myeloma Matters, you’ll learn about autologous stem cell transplantation and why it is considered the standard of care for eligible newly diagnosed patients. You’ll hear from four patients who have undergone the procedure—sometimes even twice.

Topics of discussion:

(22:45) Stem cell transplantation as a treatment option

(28:30) What type of support is needed before and after a transplant?

(40:05) Potential long-term complications from a transplant

(43:40) Fertility issues when diagnosed at a young age

(45:24) Potential concerns when considering a transplant

(50:15) Concerns about the risk of secondary cancers from maintenance therapy

(57:57) Advice to those considering a transplant

(1:07:04) Can a transplant be saved for relapse?

This episode is supported by Adaptive, Amgen, Bristol Myers Squibb, GSK, and Janssen.

To learn more about autologous stem cell transplantation, download the Multiple Myeloma: Autologous Stem Cell Transplantation information sheet here.

To learn more about multiple myeloma, visit www.themmrf.org.

Stay up to date on the MMRF’s FREE programs and resources at the MMRF Education Hub.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.

In this episode of Myeloma Matters, you’ll learn about targeted immunotherapy, a unique type of myeloma treatment that specifically targets myeloma cells. You’ll hear from three patients who have been on a targeted immunotherapy to get a sense of the patient experience and how these patients wound up receiving targeted immunotherapy.

Topics of discussion:

(0:00) Introduction to myeloma and targeted immunotherapy

(17:15) Differences between targeted immunotherapy and traditional drugs

(18:58) Preparing for CAR T-cell therapy compared to an autologous stem cell transplant

(22:34) The role of the caregiver during and after hospitalization for treatment

(32:25) Experience with a bispecific antibody

(36:21) Handling being off treatment after CAR T-cell therapy

To learn more about immunotherapy, download the Multiple Myeloma Immunotherapy booklet here.

To learn more about multiple myeloma, visit www.themmrf.org.

If you want to learn more about the MMRF’s FREE resources for patients and caregivers, visit the MMRF Education Hub.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.

In this episode, you’ll learn about smoldering multiple myeloma, a condition that precedes multiple myeloma. This podcast describes how smoldering myeloma is diagnosed, how it differs from active myeloma, and how it’s usually managed. You’ll also hear from two patients, who talk about their experience with this disease.

This episode is supported by AbbVie, Amgen, CURE, Genentech, GSK, Johnson & Johnson, Karyopharm, Legend Biotech, Pfizer, Regeneron, and Sanofi.

(0) Introduction to smoldering myeloma

(7:00) Learning the diagnosis

(8:49) The importance of finding a myeloma specialist

(17:22) The psychological burden of a smoldering myeloma diagnosis

(29:06) Patient navigators and other helpful resources

(33:15) Watchful waiting and helpful resources

(47:58) Lifestyle changes

(51:11) Caregivers

To learn more about smoldering myeloma, download the Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: Multiple Myeloma Precursor Conditions booklet here.

To learn more about multiple myeloma, visit www.themmrf.org.

If you want to learn more about the MMRF’s FREE resources for patients and caregivers, visit the MMRF Education Hub.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.

This episode of Myeloma Matters reviews the latest data on bispecific antibody (bsAb) therapy for relapsed/refractory multiple myeloma (RRMM), as discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings. Myeloma experts place research findings into clinical context and discuss strategies—including fixed-duration dosing—for preventing and managing bsAb-associated adverse events, which include cytokine release syndrome, neurotoxicity, and infection.

Topics of discussion:

• Highlights from ASCO and EHA 2024 - Teclistamab
• Highlights from ASCO and EHA 2024 - Elranatamab
• Highlights from ASCO and EHA 2024 - Linvoseltamab and ABBV-383
• GPRC5D-Directed Bispecific Antibody Therapy: Highlights From ASCO and EHA 2024
• Highlights from ASCO and EHA 2024: Infectious Complications with Bispecific Antibodies
• Highlights from ASCO and EHA 2024: Cevostamab
• Optimizing the Use of BCMA-Directed Bispecific Antibody Therapy
• Optimizing the Use of GPRC5D-Directed Bispecific Antibody Therapy

This episode is supported by Johnson & Johnson and Pfizer, Inc.

To view the virtual roundtable on the management of bispecific antibody–associated adverse events, visit myCME.

To learn more about the Multiple Myeloma Research Foundation (MMRF), visit www.themmrf.org.

Let your patients and their caregivers know about the FREE myeloma resources available on the MMRF Education Hub.

This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast, developed for health care providers, will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

Topics:

• Clinical Advances in BCMA-directed Bispecific Antibody Therapy
• Clinical Advances in GPRC5D-directed Bispecific Antibody Therapy
• Considerations for Selecting Bispecific Antibody Therapy for RRMM Management
• Mitigating CRS During Bispecific Antibody Therapy
• Mitigating Infections During Bispecific Antibody Therapy
• Mitigating GPRC5D-directed Bispecific Antibody Therapy-related Adverse Events
• Role of APPs in Helping the Patient During Bispecific Antibody Treatment
• Emerging Bispecific Antibody Constructs and New Combinations

This episode is supported by Johnson & Johnson and Pfizer, Inc.

To view the virtual roundtable on the management of bispecific antibody–associated adverse events, visit myCME.

To learn more about the Multiple Myeloma Research Foundation (MMRF), visit www.themmrf.org.

Let your patients and their caregivers know about the FREE myeloma resources available on the MMRF Education Hub.

In this episode, you’ll learn about the main side effects associated with CAR T-cell and bispecific antibody therapies, two newer multiple myeloma treatments. You’ll also hear from a patient and a nurse practitioner, who describe how these treatments are administered and share their accounts of what being on these immunotherapies is like.

(1:16) Differences between CAR T cells and autologous stem cell transplantation

(10:48) Available CAR T-cell therapies

(14:27) Available bispecific antibody therapies

(17:00) Main side effects of CAR T-cell and bispecific antibody therapies

This episode is supported by AbbVie, CURE, Genentech, Pfizer, Regeneron, and Sanofi.

To learn more about immunotherapy, view our High-Impact Topic videos here and here.

To learn more about multiple myeloma, visit www.themmrf.org.

If you want to learn more about the MMRF’s FREE resources for patients and caregivers, visit the MMRF Education Hub.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.

In this episode, we’ll be discussing caregivers—the spouses, partners, family members, and friends who play such an important role in helping myeloma patients manage everything from health care visits to the activities of everyday living.

Topics of discussion:

• The importance of being a caregiver
• Steep learning curve
• Alleviating burdens

This episode is supported by AbbVie, Amgen, Bristol Myers Squibb, CURE, Genentech, GSK, Janssen, Karyopharm, Sanofi, and Takeda.

To learn more about multiple myeloma, visit ⁠⁠themmrf.org⁠.

⁠If you want to learn more about the MMRF’s FREE resources for patients and caregivers, visit the ⁠⁠MMRF Education Hub⁠.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.